Elutia Inc - Class A
Research Elutia Inc - Class A (ELUT) on Bullrun: market cap USD 44.73M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerELUT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 44.73M
- Financial periodQ1 2026
- RevenueUSD 3.11M
- Net incomeUSD 49.84M
- Free cash flow-USD 8.29M
- Gross margin225.3%
Valuation Snapshot
latest market cap is USD 44.73M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 12.29M | USD 53.38M | -USD 46.69M | 53.7% | 0.87 | USD 36.35M | USD 3.94M | USD 27.67M |
| FY2024 | USD 14.47M | -USD 53.95M | -USD 23.31M | 46.4% | -1.86 | USD 13.24M | USD 23.85M | -USD 46.26M |
| FY2023 | USD 24.75M | -USD 37.66M | -USD 22.11M | 44.7% | -2.07 | USD 19.28M | USD 23.68M | -USD 38.60M |
| FY2022 | USD 23.85M | -USD 32.90M | -USD 21.97M | 48.8% | -2.38 | USD 16.99M | USD 24.26M | -USD 5.03M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 44.73M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 29.52M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 131.69M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 50.11M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 68.53M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 85.42M | n/a | n/a | n/a |
About Elutia Inc - Class A
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Elutia Inc - Class A's market cap?
Elutia Inc - Class A's market capitalization is USD 44.73M.
What does Elutia Inc - Class A do?
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction.